2-methyl-5-(1-methyl-1H-pyrazol-5-yl)aniline | 1340579-27-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-methyl-5-(1-methyl-1H-pyrazol-5-yl)aniline
• 英文别名: 2-methyl-5-(2-methylpyrazol-3-yl)aniline
• CAS: 1340579-27-2
• 化学式: C₁₁H₁₃N₃
• mdl: MFCD19620660
• 分子量: 187.244
• InChiKey: WPUGXXHHVSEYCQ-UHFFFAOYSA-N

物化性质

• 沸点：
  370.4±30.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为产物：
  描述：

  5-溴-2-甲基苯胺 、 alkaline earth salt of/the/ methylsulfuric acid 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 6.0h， 生成 2-methyl-5-(1-methyl-1H-pyrazol-5-yl)aniline
  参考文献：
  名称：

  代谢稳定的二苯胺衍生物抑制前列腺癌中的雄激素受体和BET蛋白

  摘要：

  雄激素受体（AR）是前列腺癌（PC）的重要驱动因素。与AR相关的耐药性仍然是去势抵抗性前列腺癌（CRPC）的主要挑战。溴结构域和末端外结构域（BET）家族是关键的AR调节剂。在这里，我们开发了几种二苯胺衍生物，并确定了化合物7d，该化合物破坏了AR和BET家族在前列腺癌中的功能，并在体外具有良好的代谢稳定性，在体内具有较高的药物暴露率。我们显示7d不仅与AR结合，抑制野生型AR（wt-AR）的反式激活和介导Enzalutamide抗性的突变体，而且还通过BET抑制作用降低了c-Myc蛋白的表达。此外，7d抑制AR阳性PC细胞的增殖具有良好的选择性，并抑制了体内表达AR-V7的VCaP和22Rv1异种移植物的生长。

  DOI：

  10.1016/j.bcp.2020.113946

文献信息

• [EN] NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE CYANOINDOLINE UTILISÉS COMME INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017125530A1

  公开（公告）日：2017-07-27

  The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF- KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及一种公式（I）的药物制剂，用于治疗和/或预防哺乳动物中的疾病，特别是用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病的NF-KB诱导激酶（NIK，也称为MAP3K14）的抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病的用途。
• DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS
  申请人：Berger Jacob

  公开号：US20100160384A1

  公开（公告）日：2010-06-24

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

  化合物的公式I：或其药用盐，其中m、n、p、q、R1、R2、R3、R4、R5和R6如本文所定义。还公开了制备这些化合物的方法，并将这些化合物用于治疗与P2X7嘌呤受体相关的疾病。
• Substituted cyanoindoline derivatives as NIK inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US11180487B2

  公开（公告）日：2021-11-23

  The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及用于哺乳动物治疗和/或预防的式(I)药物制剂，特别是用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病等疾病的NF-κB诱导激酶（NIK-又称MAP3K14）抑制剂。本发明还涉及包含此类化合物的药物组合物，以及使用此类化合物或药物组合物预防或治疗癌症、炎症性疾病、代谢紊乱（包括肥胖和糖尿病）和自身免疫性疾病等疾病。
• NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20210087182A1

  公开（公告）日：2021-03-25

  The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF- K B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.